Nigeria has received its first shipment of the long-acting injectable drug Lenacapavir, a major milestone in expanding the country’s HIV prevention options.
The development was announced Wednesday by the National AIDS, Viral Hepatitis and STIs Control Programme (NASCP) under the Federal Ministry of Health and Social Welfare.
The drug, which arrived in Nigeria on Tuesday, will be used for pre-exposure prophylaxis (PrEP) to protect people at risk of HIV infection.
NASCP said the introduction of Lenacapavir, approved by Coordinating Minister, was Muhammad Pate, and supported by the Global Fund, marks a significant step in strengthening innovative HIV prevention strategies in the country.
“As a long-acting injectable option, LEN PrEP has the potential to improve adherence and expand access for populations who may face challenges with daily oral prevention”, NASCP said.
The rollout follows months of policy discussions, global negotiations, and national preparedness efforts. During the 80th United Nations General Assembly in New York, Nigeria joined other global leaders to announce a major price reduction for Lenacapavir, from $28,000 per person per year to about $40, making it accessible to millions across Nigeria and more than 100 low- and middle-income countries.
The National Agency for the Control of AIDS (NACA) said regulatory clearance has been granted by the National Agency for Food and Drug Administration and Control (NAFDAC). Readiness assessments were conducted in 10
priority states, including Lagos, Kano, and FCT, to evaluate service delivery capacity and implementation needs. Information, education, and communication materials have also been prepared to generate awareness ahead of the rollout.
NASCP stated that the introduction of Lenacapavir demonstrates Nigeria’s commitment to innovative, evidence-based interventions to reduce new HIV infections and improve health outcomes.
The programme will work with partners to ensure the safe, strategic, and effective integration of the drug into national HIV prevention services, while advancing equitable access to prevention, testing, treatment and care.
About the Author
